The Journal Nature reported today that researchers at Oklahoma Medical Research Foundation and Emory Vaccine Center reported a method to rapidly produce human monoclonal antibodies.
Currently monoclonal antibodies rely on mice to produce the monoclonal antibodies. The researchers humanized the mouse derived pieces to accelerated and enhance the yield of suitable antibodies.
To get around that problem, researchers now "humanize" the antibodies, replacing some or all of mouse-derived pieces with human ones. The technique increased the yield from .1% to 70% in their experiment. The technique also cut the time to develop an antibody to a few weeks instead of up to 2 years.
The utility of this process is fairly plain as diagnostics and therapies can be developed on a short time horizon to blunt potential pandemics.
This research was supported by the National Institutes of Immune and Infectous Disease.
A fine article for the laymen is presented in Scientific American.